MetaCap

China Pharma (CPHI) vs Marker Therapeutics (MRKR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Marker Therapeutics (MRKR) has outperformed China Pharma (CPHI) over the past year, gaining 2.8% versus a loss of 72.6%. Over five years, MRKR leads with a -91.1% price change compared with -99.8% for CPHI. China Pharma is the larger company by market cap ($18.9 million vs $18.2 million), about 1.0 times the size.

China Pharma converts more of its revenue into profit, with a net margin of -76.9% versus -343.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CPHI-72.60%MRKR+2.83%
+430%+167%-97%
Nov 21, 20251 yearNov 20, 2026
CPHI-99.85%MRKR-91.62%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CPHI versus MRKR key metrics
MetricCPHIMRKR
Share price$0.4384$1.09
Market cap$18.86M$18.17M
1-day change-13.00%-17.42%
YTD return-63.77%-26.85%
1-year return-72.60%+2.83%
5-year return-99.84%-91.14%
EPS (TTM)$-0.42$-0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.14M$3.55M
Revenue growth (YoY)-8.49%-46.19%
Net income (latest FY)$-3.19M$-12.16M
Gross margin-3.18%—
Operating margin-78.16%-363.45%
Net margin-76.91%-342.96%
52-week high$19.19$2.46
52-week low$0.38$0.81
Distance from 52-week high-97.72%-55.69%
Analyst consensus—none
Avg. price target upside—+622.02%
Average volume1.60M711.96K
Shares outstanding43.02M16.67M
Employees2155
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRKR has outperformed CPHI by 75.4 percentage points over the past year.
  • China Pharma is more profitable, keeping -76.9 cents of every revenue dollar as net income versus -343.0 cents for Marker Therapeutics.
  • China Pharma grew revenue faster in its latest fiscal year (-8.49% vs -46.19%).

About China Pharma

CPHI stock →

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.

Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees

About Marker Therapeutics

MRKR stock →

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CPHI vs MRKR FAQ

Which is bigger, China Pharma or Marker Therapeutics?

China Pharma (CPHI) is larger, with a market capitalization of $18.86M compared with $18.17M for Marker Therapeutics (MRKR).

Which stock has performed better over the past year, CPHI or MRKR?

MRKR returned +2.83% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.

Are China Pharma and Marker Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons